MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa [2]

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 2, 2003, Pages 195-196

  Chelule, Paul K ^a   Gordon, Michelle ^a   Palanee, Thesla ^a   Page, Taryn ^a   Mosam, Anisa ^a   Coovadia, H M ^a   Cassol, Sharon ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; VINCA ALKALOID;

DNA POLYMORPHISM; GENE FREQUENCY; GENE OVEREXPRESSION; HUMAN; INDIAN; LETTER; NEGRO; PRIORITY JOURNAL; SOUTH AFRICA;

EID: 0041625733     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00151-6     Document Type: Letter

References (5)

1. Kim RB, Leake BF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functional variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
2. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72:209-19.
3. Wandel C, White JS, Hall JM, Stein M, Wood AJJ. Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
4. Cavalli SA, Hirata MH, Hirata RDC. Detection of Mbo II polymorphism at the 5′-promoter regions of CYP3A4. Clin Chem 2001;47:348-51.
5. Ameyaw M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2002;11:217-21.